Is Pharming Group NV halal to invest in?

According to Musaffa's Shariah screening methodology, Pharming Group NV (PHARM.AS) is currently classified as HALAL as of April 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Pharming Group NV a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Pharming Group NV using these criteria to determine its compliance status.

Can Muslims buy shares of Pharming Group NV?

Muslim investors may consider investing in Pharming Group NV if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Pharming Group NV classified as HALAL?

Musaffa determines the Shariah status of Pharming Group NV by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Pharming Group NV updated?

The Shariah compliance status of Pharming Group NV may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Pharming Group NV become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Pharming Group NV?

You can check the latest Shariah compliance status of Pharming Group NV on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Pharming Group NV PHARM.AS

€1.43 €0.02 (1.31%) 1D

Last Updated: May 04, 12:00 AM·AMS

PHARM.AS Shariah Compliance

Screening Methodology: AAOIFI

HALAL

Last Updated: April 16, 2026

Report Source: 2025 Annual Report

Analyst's Ratings for Pharming Group NV (PHARM.AS)

Based on 14 analysts giving stock ratings to Pharming Group NV in the past 3 months

Strong
SellSellHoldBuyStrong
Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Pharming Group NV. Stock Analysis PHARM.AS

Netherlands Health Care Small Cap Report: 2025 Annual

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 426 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

Key Statistics of Pharming Group NV (PHARM.AS)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

€1.39€1.44

Today's Open

€1.45

Volume

9.97M

P/E Ratio (TTM)

415.33

52 Week Range

€0.80€1.82

Market Cap

1.21B

Avg. Volume

4.39M

Dividend Yield

Financial Metrics & Statements of Pharming Group NV (PHARM.AS)

FAQ's for Pharming Group NV (PHARM.AS)

According to Musaffa’s Shariah screening methodology, Pharming Group NV (PHARM.AS) is currently classified as HALAL as of April 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.